Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension

Circulation

Volumn 126, Issue 9, 2012, Pages 1087-1098

  White, Kevin ^a   Johansen, Anne Katrine ^a   Nilsen, Margaret ^a   Ciuclan, Loredana ^b   Wallace, Emma ^a   Paton, Leigh ^a   Campbell, Annabel ^a   Morecroft, Ian ^a   Loughlin, Lynn ^a   McClure, John D ^c   Thomas, Matthew ^b   Mair, Kirsty M ^c   MacLean, Margaret R ^a,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Animal; Cardiovascular diseases; Estrogens; Hypertension; Metabolism; Models; Pulmonary

Indexed keywords

16ALPHA HYDROXYESTRONE; CYTOCHROME P450 1B1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; MALE; MITOGENESIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; UPREGULATION;

ANIMALS; ANOXIA; ARYL HYDROCARBON HYDROXYLASES; CELL HYPOXIA; CELLS, CULTURED; CHRONIC DISEASE; ENZYME INDUCTION; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; HYDROXYESTRONES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; MICE; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STILBENES; UP-REGULATION;

EID: 84865446457     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.062927     Document Type: Article

References (47)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43-S54.
2. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S20-S31.
3. Cool CD, Groshong SD, Oakey J, Voelkel NF Pulmonary hypertension: cellular and molecular mechanisms. Chest. 2005;128:565S-571S (Pubitemid 43054120)
4. Mitani Y, Ueda M, Komatsu R, Maruyama K, Nagai R, Matsumura M, Sakurai M Vascular smooth muscle cell phenotypes in primary pulmonary hypertension. Eur Respir J 2001;17:316-320. (Pubitemid 32600593)
5. Tuder RM, Groves B, Badesch DB, Voelkel NF Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275-285. (Pubitemid 24165948)
6. Pak O, Aldashev A, Welsh D, Peacock A The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J 2007;30:364-372. (Pubitemid 47201724)
7. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012;141:363-373.
8. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122:156-163.
9. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030.
10. Morse JH, Horn EM, Barst RJ Hormone replacement therapy: a possible risk factor in carriers of familial primary pulmonary hypertension. Chest. 1999;116:847. (Pubitemid 29428518)
11. Masi AT Editorial: pulmonary hypertension and oral contraceptive usage. Chest. 1976;69:451-453.
12. Pugh ME, Hemnes AR Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond Engl). 2010;6:285-296.
13. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y, Baker AH, MacLean MR Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH Physiol Genomics. 2011;43:417-437.
14. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR The serotonin transporter, gender, and 17beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res. 2011;90: 373-382.
15. Tofovic SP, Zhang X, Zhu H, Jackson EK, Rafikova O, Petrusevska G 2-ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul Pharmacol. 2008;48:174-183.
16. West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA, Lane K, Meyrick B, Loyd J Gene expression in bmpr2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics. 2008;1:45.
17. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA III Alterations in oestrogen metabolism: Implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 2009;34:1093-1099.
18. Ciolino H, MacDonald C, Memon O, Dankwah M, Yeh GC Dehydroepiandrosterone inhibits the expression of carcinogen-activating enzymes in vivo. Int J Cancer. 2003;105:321-325. (Pubitemid 36570043)
19. Bonnet S, Dumas-de-La-Roque E, Be'gueret H, Marthan R, Fayon M, Dos Santos P, Savineau JP, Baulieu EE Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A 2003;100:9488-9493. (Pubitemid 37033955)
20. Murray GI, Melvin WT, Greenlee WF, Burke MD Regulation, function, and tissue-specific expression of cytochrome p450 cyp1b1. Annu Rev Pharmacol Toxicol. 2001;41:297-316. (Pubitemid 32390115)
21. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF Cytochrome p450 1b1 (cyp1b1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 2000;60:3440-3444. (Pubitemid 30482162)
22. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, Melvin WT Tumor-specific expression of cytochrome p450 cyp1b1. Cancer Res. 1997;57:3026-3031. (Pubitemid 27315056)
23. McKay JA, Melvin WT, Ah-See AK, Ewen SW, Greenlee WF, Marcus CB, Burke MD, Murray GI Expression of cytochrome p450 cyp1b1 in breast cancer. FEBS Lett. 1995;374:270-272.
24. McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE, Parkin D, Murray GI Cytochrome p450 cyp1b1 overexpression in primary and metastatic ovarian cancer. Br J Cancer. 2001; 85:242-246. (Pubitemid 32695746)
25. McFadyen MC, Melvin WT, Murray GI Cytochrome p450 cyp1b1 activity in renal cell carcinoma. Br J Cancer. 2004;91:966-971. (Pubitemid 39273792)
26. Stoilov I, Akarsu AN, Sarfarazi M Identification of three different truncating mutations in cytochrome p4501b1 (cyp1b1) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the glc3a locus on chromosome 2p21. Hum Mol Genet. 1997;6:641-647. (Pubitemid 27142117)
27. Jennings BL, Sahan-Firat S, Estes AM, Das K, Farjana N, Fang XR, Gonzalez FJ, Malik KU Cytochrome p450 1b1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertension. 2010;56:667-674.
28. Buters JT, Doehmer J, Gonzalez FJ Cytochrome p450-null mice. Drug Metab Rev. 1999;31:437-447. (Pubitemid 29222671)
29. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR Contribution of the 5-ht(1b) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-ht(1b)-receptor knockout mice and the 5-ht(1b/1d)-receptor antagonist gr127935. Circ Res. 2001;89: 1231-1239. (Pubitemid 34627883)
30. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, Walker C, Westwick J, Thomas M A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;184:1171-1182.
31. Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP A new selective and potent inhibitor of human cytochrome p450 1b1 and its application to antimutagenesis. Cancer Res. 2001;61:8164-8170. (Pubitemid 33091608)
32. Welsh DJ, Peacock AJ, MacLean M, Harnett M Chronic hypoxia induces constitutive p38 mitogen-activated protein kinase activity that correlates with enhanced cellular proliferation in fibroblasts from rat pulmonary but not systemic arteries. Am J Respir Crit Care Med. 2001;164:282-289. (Pubitemid 34001296)
33. Morecroft I, Pang L, Baranowska M, Nilsen M, Loughlin L, Dempsie Y, Millet C, MacLean MR In vivo effects of a combined 5-ht1b receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res. 2010;85:593-603.
34. Conover WJ, Iman RL Analysis of covariance using the rank transformation. Biometrics. 1982;38:715-724. (Pubitemid 13286346)
35. Lewis JS, Thomas TJ, Pestell RG, Albanese C, Gallo MA, Thomas T Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. J Mol Endocrinol. 2005;34:91-105. (Pubitemid 40305552)
36. Liu Y, Suzuki YJ, Day RM, Fanburg BL Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ Res. 2004;95:579-586. (Pubitemid 39274372)
37. Jasmin JF, Mercier I, Hnasko R, Cheung MW, Tanowitz HB, Dupuis J, Lisanti MP Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc Res. 2004;63:747-755. (Pubitemid 39078689)
38. Luby TM Targeting cytochrome p450 cyp1b1 with a therapeutic cancer vaccine. Expert Rev Vaccines. 2008;7:995-1003.
39. Umar S, Iorga A, Matori H, Nadadur RD, Li J, Maltese F, van der Laarse A, Eghbali M Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med. 2011;184:715-723.
40. Xu DQ, Luo Y, Liu Y, Wang J, Zhang B, Xu M, Wang YX, Dong HY, Dong MQ, Zhao PT, Niu W, Liu ML, Gao YQ, Li ZC Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats. Respir Res. 2010;11:182.
41. Earley S, Resta TC Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol. 2002;283:L86-93. (Pubitemid 34764544)
42. Resta TC, Kanagy NL, Walker BR Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol. 2001;280:L88-L97.
43. Tofovic SP, Salah EM, Mady HH, Jackson EK, Melhem MF Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol. 2005;46:430-437. (Pubitemid 41407569)
44. Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G 2-methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol. 2006;45:358-367. (Pubitemid 44765298)
45. Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G 2-Methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul Pharmacol. 2009; 51:190-197.
46. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Tan J, Meldrum DR Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxidedependent mechanism. Am J Physiol Regul Integr Comp Physiol. 2008; 295:R1486-R1493.
47. Lahm T, Crisostomo PR, Markel TA, Wang M, Wang Y, Weil B, Meldrum DR Exogenous estrogen rapidly attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction. Shock. 2008;30:660-667.